Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Goodsomnia the world’s first non-invasive solution for snoring treatment.

Reference number
Coordinator GOODSOMNIA AB
Funding from Vinnova SEK 500 000
Project duration May 2019 - November 2019
Status Completed

Important results from the project

The main purpose of the project has been to conduct a comprehensive feasibility study and determine the best commercialization strategy. It has mainly focused on market entry where the markets where the company will start have been identified, IPR strategy where the company has chosen to proceed with patent protection of its unique product in large parts of the world based on the approved Swedish patent, and identify various initial client groups. where unique value propositions have been developed.

Expected long term effects

The company now has an overall plan with a strategy for the market introduction with determined first markets and clear customer offerings based on identified needs, analysis of the regulatory requirements in the determined markets, protection of IP through patent applications and a business plan with a much more developed market analysis and sales forecasts. This has created much better conditions for a successful launch and additional funding.

Approach and implementation

The countries in question for the first year of commercialization have been analyzed to determine which the company should proceed with and interviews have been conducted to validate offers and get feedback. The regulatory requirements for the identified launch markets have been analyzed with specialists and partners. More detailed analysis has also been made of sales forecasts, both for the launch markets and for the continued global commercialization where also a continued roadmap has been further developed.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 7 February 2020

Reference number 2019-02271